PortViewPortView
Apollomics logo

Apollomics (APLMW) Stock Analysis

NASDAQHealthcareBiotechnology

$0.01-17.39%
1-year price historyRange $0.01 – $0.03
52-week range$0.01
$0.01$0.03

What Apollomics does

Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements. The company was co-founded by Liang Yu Guo and Sanjeev Redkar in 2015, with its main operations based in Foster City, California.

Key metrics

Market cap
$168.49M
EPS (TTM)
$-279.00
Beta
2.09
Dividend yield
0.00%
Revenue / share
$20.19
50-day avg
$0.03
200-day avg
$0.03
52-week high
$0.03
52-week low
$0.01
CEO
Hung-Wen Chen

ETFs linked to APLMW

Broad-market and Healthcare sector ETFs an investor holding Apollomics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how APLMW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze APLMW in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Apollomics?
Apollomics trades under the ticker APLMW on NASDAQ.
Which exchange is APLMW listed on?
APLMW is listed on NASDAQ.
What sector does Apollomics operate in?
Apollomics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze APLMW in a portfolio?
PortView shows APLMW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.